'J clin oncol' presentation slideshows

Regression, correlation and liquid association in complex genomic data analysis

1.43k views • 119 slides

Cranberry

Cranberry. Vaccinium macrocarpon-cultivated in Washington Long history of use The mechanism was thought to be urine acidification Now E. coli (other pathogens also) adhesion inhibitors are known to be present but not in other juices. Several proanthocyanidins are likely the active compounds

2.12k views • 102 slides

Advances in the adjuvant treatment of colorectal cancer

Stefano Cascinu Clinica di Oncologia Medica Ancona. Advances in the adjuvant treatment of colorectal cancer . COLON CANCER 2004. Estimated New Cases in Europe and Italy Death UE: 213.000 110.000 I: 32.000 16.000 .

1k views • 81 slides

Phase II Study of Temozolomide and Thalidomide in

Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors J Clin Oncol . 2006 Jan 20;24(3):401-6. Vs ??? CR ???. ?????????????????. Outline. Classification and grading of NET Introduction to temozolomide Inclusion and exclusion criteria

523 views • 40 slides

Chemotherapy Induced Nausea and Vomiting (CINV ) Causes, Challenges, Evaluation and Optimizing Clinical Management

Innovation ? Investigation ? Application. Chemotherapy Induced Nausea and Vomiting (CINV ) Causes, Challenges, Evaluation and Optimizing Clinical Management . Program Co-Chairman Lee S. Schwartzberg, MD, FACP Medical Director, The West Clinic Supportive Oncology Services

1.84k views • 38 slides

Monica Morrow MD Chief, Breast Surgery Service Anne Burnett Windfohr Chair of Clinical Oncology Memorial Sloan-Kettering

18 th Annual Perspectives in Breast Cancer New York, NY. Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065. 18 August 2012. Treatment Decision Making for DCIS. Monica Morrow MD Chief, Breast Surgery Service Anne Burnett Windfohr Chair of Clinical Oncology

680 views • 37 slides

Is there Long-Term Benefit from Maintenance Rituximab?

Is there Long-Term Benefit from Maintenance Rituximab?. Emanuele Zucca, MD Oncology Institute of Southern Switzerland (IOSI) Swiss Group for Clinical Cancer Research (SAKK). Rationale and aim of maintenance in haematological malignancies.

562 views • 37 slides

Treatment strategies to maximise patient benefit in metastatic colorectal cancer

Treatment strategies to maximise patient benefit in metastatic colorectal cancer. Associate Professor Winston Liauw Cancer Care Centre St George Hospital @ wsliauw. Case discussion.

513 views • 37 slides

FIRST-LINE THERAPY FOR ADVANCED NSCLC

FIRST-LINE THERAPY FOR ADVANCED NSCLC. Rogerio C. Lilenbaum, MD Clinical Associate Professor of Medicine University of Miami School of Medicine Director, Thoracic Oncology Program The Mount Sinai Comprehensive Cancer Center Miami Beach, FL. QUESTIONS FOR DISCUSSION.

583 views • 34 slides

Pharmacogenetics of Tamoxifen An FDA Perspective

Pharmacogenetics of Tamoxifen An FDA Perspective. Clinical Pharmacology Subcommittee October 18, 2006 Rockville, Maryland. NAM Atiqur Rahman, Ph.D. Director Division of Clinical Pharmacology 5 Office of Clinical Pharmacology Office of Translational Sciences CDER, FDA.

667 views • 33 slides

Evidence-base approach in the perioperative management and follow-up strategy for colon cancer

Evidence-base approach in the perioperative management and follow-up strategy for colon cancer. Hester YS Cheung Department of surgery Pamela Youde Nethersole Eastern Hospital. Common scenario. M/54 No family history of carcinoma of colon Presented with dizziness

339 views • 33 slides

Ruxolinib for Myelofibrosis

?????????????????. Ruxolinib for Myelofibrosis. VS ??? /R4 ???. N Engl J Med 2012;366:799-807. N Engl J Med 2012;366:787-98. Myelofibrosis. Epidemiology Mainly in middle aged and elder patients, the median age at presentation is 67 y/o Clinical Manifestation Constitutional symptoms

764 views • 29 slides

Total Body Irradiation

864 views • 26 slides

Adductor Compartment STS - Does method of treatment affect outcome?

Adductor Compartment STS - Does method of treatment affect outcome?. Anup Pradhan, Yiu-Chung Cheung Birmingham Medical School, UK Supervisors: Mr Robert J Grimer Royal Orthopaedic Hospital, Birmingham, UK Dr Peter Ferguson Mount Sinai Hospital, Toronto, Canada. Background.

460 views • 25 slides

Ramon V. Tiu, MD | July 12, 2013

Molecular Mutations in Myeloid Malignancies: Practical Applications in Clinical Hematology and Oncology . Ramon V. Tiu, MD | July 12, 2013. Objectives. To provide an overview of new genetic discoveries in Myeloid neoplasms To discuss the frequency of these mutations based on disease type

485 views • 25 slides

Taking the tablets, Do we / should we?

387 views • 24 slides

366 views • 23 slides

Prognostic value of myogenic differentiation in adult soft tissue sarcomas (STS) A study of 855 cases from the French S

Prognostic value of myogenic differentiation in adult soft tissue sarcomas (STS) A study of 855 cases from the French Sarcoma Group. N Stock, MC Chateau, F Collin, L Guillou, A Leroux, B Marques, JJ Michels, D Ranchere, YM Robin, P Terrier, M Trassard, I Valo and JM Coindre.

434 views • 17 slides

Methylation and Cancer

Methylation and Cancer. Andrew J. Pierce. Microbiology, Immunology and Molecular Genetics Graduate Center for Toxicology Markey Cancer Center University of Kentucky. MI616 Spring 2007. Some considerations of methylation in cancer:. cytosine methylation inactivating genes

331 views • 15 slides

Psychooncology for non-psychooncologists

Psychooncology for non-psychooncologists. A Kiss 21.05.08. What do cancer patients want from their oncologists?. Technical Competence (Disease) Psychosocial Competence (Illness). Communication with patients and relatives. Giving bad news Dealing with emotions Giving complex informations

222 views • 15 slides